RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors

被引：0
|
作者：
Tessari, A. [1 ]
Palmieri, D. [1 ]
Pawlikowski, M. [1 ]
Parbhoo, K. [1 ]
Foray, C. [1 ]
Fassan, M. [2 ]
La Perle, K. [3 ]
Rulli, E. [4 ]
Fabbri, A. [5 ]
Ganzinelli, M. [6 ]
Embrione, V. [1 ]
Broggini, M. [4 ]
Amann, J. [7 ]
Carbone, D. [8 ]
Garassino, M. [5 ]
Croce, C. [1 ]
Coppola, V. [1 ]
机构：
[1] Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH 43210 USA
[2] Univ Padua, Cytol & Pathol, Padua, Italy
[3] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA
[4] IRCCS Ist Ric Farmacol Mario Negri, Oncol, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[6] IRCCS Ist Nazl Tumori, Milan, Italy
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[8] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
PARP inhibitors; RanBP9; Cisplatin;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.02-065
引用
收藏
页码：S2122 / S2123
页数：2
相关论文
共 22 条
  • [1] RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients
    Tessari, Anna
    Parbhoo, Kareesma
    Pawlikowski, Meghan
    Fassan, Matteo
    Rulli, Eliana
    Foray, Claudia
    Fabbri, Alessandra
    Embrione, Valerio
    Ganzinelli, Monica
    Capece, Marina
    Campbell, Moray J.
    Broggini, Massimo
    La Perle, Krista
    Farina, Gabriella
    Cole, Sara
    Marabese, Mirko
    Hernandez, Marianna
    Amann, Joseph M.
    Pruneri, Giancarlo
    Carbone, David P.
    Garassino, Marina C.
    Croce, Carlo M.
    Palmieri, Dario
    Coppola, Vincenzo
    ONCOGENE, 2018, 37 (50) : 6463 - 6476
  • [2] RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients
    Anna Tessari
    Kareesma Parbhoo
    Meghan Pawlikowski
    Matteo Fassan
    Eliana Rulli
    Claudia Foray
    Alessandra Fabbri
    Valerio Embrione
    Monica Ganzinelli
    Marina Capece
    Moray J. Campbell
    Massimo Broggini
    Krista La Perle
    Gabriella Farina
    Sara Cole
    Mirko Marabese
    Marianna Hernandez
    Joseph M. Amann
    Giancarlo Pruneri
    David P. Carbone
    Marina C. Garassino
    Carlo M. Croce
    Dario Palmieri
    Vincenzo Coppola
    Oncogene, 2018, 37 : 6463 - 6476
  • [3] Multiple DNA-damage response pathways are modulated by RANBP9 protein in NSCLC
    Tessari, Anna
    Parbhoo, Kareesma
    Pawlikowski, Meghan
    Fassan, Matteo
    Rulli, Eliana
    Foray, Claudia
    Fabbri, Alessandra
    Embrione, Valerio
    Ganzinelli, Monica
    Capece, Marina
    Broggini, Massimo
    Farina, Gabriella
    Marabese, Mirko
    Garassino, Marina C.
    Croce, Carlo
    Palmieri, Dario
    Coppola, Vincenzo
    CANCER RESEARCH, 2018, 78 (13)
  • [4] RanBP9 protects cells from genotoxic stress and increased expression is predictive of worse response to platinum in NSCLC patients
    Tessari, Anna
    Parbhoo, Kareesma
    Pawlikowski, Meghan
    Fassan, Matteo
    Rulli, Eliana
    Foray, Claudia
    Fabbri, Alessandra
    Embrione, Valerio
    Ganzinelli, Monica
    Capece, Marina
    Campbell, Moray J.
    Broggini, Massimo
    La Perle, Krista
    Farina, Gabriella
    Cole, Sara
    Marabese, Mirko
    Amann, Joseph M.
    Carbone, David P.
    Garassino, Marina C.
    Croce, Carlo M.
    Palmieri, Dario
    Coppola, Vincenzo
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [5] Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells
    Palmieri, Dario
    Scarpa, Mario
    Tessari, Anna
    Uka, Rexhep
    Amari, Foued
    Lee, Cindy
    Richmond, Timothy
    Foray, Claudia
    Sheetz, Tyler
    Braddom, Ashley
    Burd, Christin E.
    Parvin, Jeffrey D.
    Ludwig, Thomas
    Croce, Carlo M.
    Coppola, Vincenzo
    ONCOTARGET, 2016, 7 (14) : 18371 - 18383
  • [6] Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells
    Palmieri, Dario
    Scarpa, Mario
    Tessari, Anna
    Uka, Rexhep
    Amari, Foued
    Lee, Cindy
    Richmond, Timothy
    Sheetz, Tyler
    Parvin, Jeffrey
    Ludwig, Thomas
    Croce, Carlo M.
    Coppola, Vincenzo
    CANCER RESEARCH, 2015, 75
  • [7] KRAS as predictive biomarker of response to checkpoint inhibitors in NSCLC
    Addeo, A.
    Torralvo, J.
    Dietrich, P-Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S114 - S115
  • [8] A Novel 5-miR Signature Shows Potential as a Diagnostic Tool and as a Predictive Biomarker of Cisplatin Response in NSCLC
    Mac Donagh, L.
    Gray, S.
    Gallagher, M.
    Ffrench, B.
    Gasch, C.
    Young, V.
    Ryan, R.
    Nicholson, S.
    Leonard, N.
    Finn, S.
    Cuffe, S.
    O'Byrne, K.
    Barr, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2122 - S2122
  • [9] Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
    Miller, Rowan E.
    Elyashiv, Osnat
    El-Shakankery, Karim H.
    Ledermann, Jonathan A.
    ONCOTARGETS AND THERAPY, 2022, 15 : 1105 - 1117
  • [10] RANBP9 presence affects levels of Tip60 and activated p53 in lung cancer cells in response to DNA damage
    Soliman, Shimaa
    Orlacchio, Arturo
    Tessari, Anna
    Capece, Marina
    Visone, Rosa
    Croce, Carlo
    Palmieri, Dario
    Coppola, Vincenzo
    CANCER RESEARCH, 2019, 79 (13)
123